Drug Profile
TT 223
Alternative Names: G1 - Transition Therapeutics; TT-223Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Transition Therapeutics
- Class Antihyperglycaemics; Biguanides; Gastrointestinal hormones; Hormones; Neuropeptides; Peptide hormones
- Mechanism of Action Gastrin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 17 Sep 2010 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (SC)
- 03 Feb 2010 Safety and efficacy data from a phase II trial in Type-2 diabetes mellitus released by Transition Therapeutics
- 10 Feb 2009 Transition Therapeutics completes enrolment in its phase II trial for Type 2 diabetes mellitus in USA